NCT07531043 Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in Adults
| NCT ID | NCT07531043 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Alcon Research |
| Condition | Ocular Hyperemia |
| Study Type | INTERVENTIONAL |
| Enrollment | 230 participants |
| Start Date | 2026-09-30 |
| Primary Completion | 2027-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 230 participants in total. It began in 2026-09-30 with a primary completion date of 2027-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of an investigational ophthalmic solution in adults with ocular redness due to minor eye irritations.
Eligibility Criteria
Key Inclusion Criteria: * Capable of giving signed informed consent and comply with the requirements listed in the Informed Consent Form. * Willing and able to follow all instructions and attend all study visits. * History of redness relief eyedrop use within the last 6 months, or an interest in using over-the-counter redness relief drops, or would benefit from the use of redness relief drops in the investigator's opinion. * Baseline investigator-assessed ocular redness score of 0.5 or higher in at least one eye at Visit 1 when applicable and a score of greater than 1.0 in both eyes on a 5-point scale prior to randomization on Day 1 (Visit 2). * Other protocol-defined inclusion criteria may apply. Key Exclusion Criteria: * Known contraindications or sensitivity to the use of any of the investigational product(s) or their components, or any other medication required by the protocol. * Ocular surgical intervention within 6 months prior to Visit 1 or during the study. * Any ocular condition that, in the opinion of the investigator, may compromise the subject's safety or study specific parameters. * Use of any of the prohibited medications or devices as specified in the study protocol. * Out-of-range vital signs (blood pressure and/or pulse rate) as defined in the study protocol. * Abnormal intraocular pressure. * Other protocol-defined exclusion criteria may apply.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07531043 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Ocular Hyperemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07531043 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 230 participants.
Is NCT07531043 currently recruiting?
Yes, NCT07531043 is actively recruiting participants. Contact the research team at alcon.medinfo@alcon.com for enrollment information.
Where is the NCT07531043 trial being conducted?
This trial is being conducted at Los Angeles, United States, Newport Beach, United States, Pittsburg, United States, Louisville, United States and 5 additional locations.
Who is sponsoring the NCT07531043 clinical trial?
NCT07531043 is sponsored by Alcon Research. The trial plans to enroll 230 participants.